Potential new treatment pathway for bladder cancer скачать в хорошем качестве

Potential new treatment pathway for bladder cancer

There is hope for a more effective immunotherapy against bladder cancer thanks to a discovery by University of Queensland (UQ) researchers at Queensland’s Translational Research Institute (TRI). Researchers from UQ’s Frazer Institute have discovered the mechanism that bladder cancer uses to suppress the immune system’s natural killer (NK) cells. The discovery could see researchers apply existing drugs to target and neutralise the mechanism, allowing the NK immune cells to kill the cancer. The TRI-based team led by Associate Professor Fernando Guimaraes said the research, published in The Lancet’s prestigious journal, eBioMedicine, could lead to new bladder cancer therapies within three to five years. “For us, it is all about unlocking the power of immunotherapy,” A/Prof. Guimaraes said. The team found that bladder cancer suppresses immune cells by releasing a protein called TGF-β and blocking that protein may offer a new therapy for some of the worst types of the cancer. “Our research is a step towards clinical trials to explore the effectiveness of TGF-β inhibitors combined with NK cell-based therapies.” Bladder cancer is the ninth most common malignancy in the world, with more than 3,000 people diagnosed in Australia and more than 1,000 dying in 2023. It occurs when cells in the lining of the bladder grow and divide in an abnormal, uncontrolled way. The bladder cancer immune suppression mechanism was discovered by A/Prof. Guimaraes’ PhD candidate Joshua Wong. “It really was a eureka moment and it’s extremely motivating to come in here every day and do your best work, because ultimately we are trying to find a cure for cancer,” Mr Wong said. Bladder cancer patient Mr. Gary Horay said the discovery gave him hope of more effective treatment options. “This research is just amazing and for those of us living with bladder cancer, it’s discoveries like this that give us hope. It’s the hope that keeps you going,” he said. Gary’s prognosis is good because his cancer was caught early. He felt generally unwell and had difficulty passing urine, so he went to the doctor and tests revealed the cancer. “The lesson from my case is, get checked. If you think there is something wrong, get it checked,” Gary said. The standard treatment for early-stage bladder cancer is endoscopic surgery, occasionally combined with chemotherapy or immunotherapy. For advanced disease, more invasive surgery or radiotherapy is combined with chemotherapy or immunotherapy, which are associated with significant ill health and life-long impacts on quality of life. A/Prof. Guimaraes said NK cells are components of the immune system that naturally attack cancer cells and are a focus of emerging cancer treatments, including antibody-based immunotherapies. The side-effects of immunotherapy for cancer are generally less severe than chemo and radio therapy. His team has used patient samples, as part of a collaboration with UQ researchers and Princess Alexandra Hospital urologists, including Dr Handoo Rhee, Professor Eric Chung and Dr Alice Nicol. They conducted tests and analysis using TRI Core facilities including flow cytometry, microscopy, histology and the Biological Research Facility. For information and interviews, contact: Alex Smith 0412 796183 media@tri.edu.au TV news please note: A/Prof Guimaraes and team available for interview Wednesday 21 August at TRI. Bladder cancer survivor Gary Horay available for interview at home. About TRI: TRI is a collaboration between four partners: Queensland Health, The University of Queensland, QUT and Mater Research. TRI provides world-class research facilities, links to clinicians and clinical trial facilities and expertise, links to industry, governments, and funding bodies, and an education and training program to help grow the future workforce. It is also the base of the Translational Science Hub, a global mRNA vaccine hub delivered in partnership with the Queensland Government, Sanofi, UQ and Griffith University. Proudly supported by the Queensland Government, in 2026 TRI will open Australia’s first scale-up biomedical manufacturing facility for early-phase startup biotech companies to establish, build, test and develop their own drugs and medical devices, enhancing our sovereign capability. Visit: tri.edu.au